Skip to main content

Table 1 Baseline characteristics

From: A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma

Characteristic

Solid tumour N = 19

Haematological malignancy N = 28

Combined N = 47

Sex

 Male

9

18

27

 Female

10

10

20

Median age (range), years

59.2 (39.4–70.8)

49.0 (21.7–79.4)

53.1 (21.7–79.4)

Median no. of prior lines of systemic therapy (range)

2 (0–8)

4 (1–10)

3 (0–10)

ECOG performance status

 0

7

10

17

 1

12

18

30

Histology

Colorectal 4

cHL 15

 

Lung 4

DLBCL 3

Upper GI 3

AITL 4

Cervix 2

PTCLNOS 2

Endometrial 1

Indolent B-cell NHL 3

Breast 1

GZL 1

Peritoneal 1

 

Neuroendocrine 1

Head and neck SCC 1

Meningioma 1

Stage

 III

0

4

N/A

 III or IIIS

2

6

 IV

17

18

Baseline HR23B status (IHC)

 Positive (6–7)

15

17

32

 Negative (0–5)

2

9

11

 Not available

2

2

4

  1. GI gastrointestinal, ECOG Eastern Cooperative Oncology Group, cHL classic Hodgkin lymphoma, AITL angio-immunoblastic T-cell lymphoma, DLBCL diffuse large B-cell lymphoma, GZL grey zone lymphoma, HR23B UV excision repair protein RAD23, IHC immunohistochemistry, NHL non-Hodgkin lymphoma, PTCLNOS Peripheral T-cell lymphoma not otherwise specified